Tech Company Financing Transactions
Ocelot Bio Funding Round
On 3/23/2022, Ocelot Bio announced $36 million in funding from RA Capital, Venrock and Vivo Capital.
RA Capital (Lead Investor)
Venrock (Lead Investor)
Vivo Capital (Lead Investor)
Proceeds purposes were not disclosed.
Private & Independent
Ocelot Bio, Inc., is a clinical-stage biopharmaceutical company dedicated to bringing meaningful therapeutic interventions to patients in dire need due to complications of decompensated (advanced) cirrhosis, in particular hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites.
Browse more venture capital transactions:
Prev: 3/23/2022: Waitroom venture capital transaction
Next: 3/23/2022: Ride1Up venture capital transaction
Share this article
About Our VC Transactions Data
We report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs